



BIOPRODUCTION **SUMMIT**

ADVANCES IN THERAPEUTIC PROTEIN PRODUCTION

AGENDA - TUESDAY, NOV 3, 2015

SESSION - IV

Case studies of Biosimilar Development

7:30 Continental Breakfast/Networking

8:45 Chairman's Opening Remarks

Dr. Sarfaraz K. Niazi

Executive Chairman, Therapeutic Proteins International, LLC

9:00 Clone-specific improvement in productivity and glycosylation fidelity

Bill Whitford

Senior Manager Cell Culture, GE Healthcare

9:30 Next generation monoclonal Antibody development using modified cellular platform

Dr Maloy Ghosh

CSO, Theramyt Novobiologics

10:00 A New Biobetter Therapeutic - Development and Manufacturing, A Case Study

Michiel E. Ultee, Ph.D

Principal, Ulteemit BioConsulting, Hillsborough, NJ, and Kent E. Pryor, Ph.D., Chief Operating Officer, ZZ Biotech, Houston, TX.

10:30 Critical Ambiguities in the Biologics Price Competition and Innovation Act (BPCIA) of 2010 Challenge Both Reference and Biosimilar Drug Product Sponsors

Verne A. Luckow, Ph.D., J.D.

Managing Member, The Intellectual Property Law Office of Verne A. Luckow

11:00 Exhibitors & Posters

11:45 Lunch

SESSION - V

Development of Novel Biotherapeutics

1:00 Chairman's Opening Remark

Eric Carlson

Vice President and Chief Business Officer, Protein Metrics Inc.

1:15 Using the endoplasmic reticulum as a physiological test tube: predicting undesirable solution properties of mAb clones by analyzing the overexpression-induced cell phenotypes

Haruki Hasegawa

Principal Scientist, Therapeutic Discovery - Biologics, Amgen Inc.

1:45 Accelerate development of novel biotherapeutics with data analysis and reporting tools for rapid, comprehensive PTM and sequence variant analysis

Eric Carlson

Vice President and Chief Business Officer, Protein Metrics Inc.

2:15 How to achieve CHO process efficiency without sacrificing quality or performance

Doan Tran

Process Science Manager, Thermo Fisher Scientific

2:45 CaptureSelect™ Technology: Introducing One-Step Selectivity in the Purification of Biological Products

Bruce Dawson

Business Development Americas, Thermo Fisher Scientific

3:15 Refreshment break/Best Poster Awards

SESSION - VI

Transient Gene Expression for Bioproduction

4:00 Chairman's Opening Remark

Henry C. Chiou

Associate Director, Cell Biology, Life Science Solutions Thermo Fisher Scientific

4:10 Optimizing CHO Expression for Rapid Identification of Relevant Drug Candidates with Flow Electroporation

James Brady

Vice President, Technical Applications, Maxcyte Inc.

4:40 Increasing performance of CHO transient expression above that of HEK293-based systems

Henry C. Chiou

Associate Director, Cell Biology, Life Science Solutions Thermo Fisher Scientific

5:10 Use of recent electroporation technology for efficient transient gene expression production of monoclonal antibodies

Nancy Guillen

Post Doctoral Research Fellow, Boehringer Ingelheim

5:45 End of Day